Inclusion Criteria:

          -  Confirmed diagnosis of Stage III or Stage IV NSCLC and have received ≥ 1 line of prior
             systemic therapy in the locally advanced or metastatic setting

          -  Have at least 1 resectable lesion to generate TIL

          -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors, version
             1.1 (RECIST 1.1)

          -  Male or female, ≥ 18 years of age

          -  Body weight > 30 kg

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and estimated
             life expectancy of ≥ 3 months

          -  Adequate bone marrow function at screening

          -  Adequate organ function at screening

          -  If the patient is of childbearing potential or their partner(s) is of childbearing
             potential, they must agree to use highly effective method of contraception while on
             study and for 6 months after receiving all protocol-related therapy.

        Exclusion Criteria:

          -  Must not have a history of other malignancies, except for adequately treated
             nonmelanoma skin cancer, curatively treated in-situ cancer of the cervix,
             curatively-treated thyroid cancer, or other solid tumors curatively treated with no
             evidence of disease for ≥ 3 years

          -  Patients may not have received prior cell therapy

          -  Patients may not have received prior anti PD-1 or anti PD-L1 inhibitors

          -  Active or prior documented autoimmune or inflammatory disorders

          -  History of primary immunodeficiency, history of allogeneic organ transplant that
             requires therapeutic immunosuppression

          -  Received live or attenuated vaccination within 28 days prior to the start of NMA-LD

          -  History of hypersensitivity to cyclophosphamide, fludarabine, dimethyl sulfoxide
             (DMSO) or IL-2

          -  Known allergic reaction to antibiotics of the aminoglycoside group (ie, streptomycin,
             gentamicin)

          -  Mean QT interval ≥ 470 msec

          -  Decreased cardiac function as evidenced by a left ventricular ejection fraction of <
             45%

          -  Uncontrolled intercurrent illness

          -  Patients who have obstructive or restrictive pulmonary disease and have a documented
             FEV1 (forced expiratory volume in 1 second) of ≤ 60%

          -  Active central nervous system metastases and/or leptomeningeal disease

          -  Current or prior use of immunosuppressive medication within 28 days before the first
             study treatment